Company / Profit Margin
Regeneron Pharmaceuticals Profit Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
31.4%
FY2025
5-year range
30.1% / 41.3%
FY2021-FY2025
Trend
+1.1%
vs FY2024
Sector context
#18 of 146
Health Care
What the data says
Regeneron Pharmaceuticals's profit margin of 31.4% is higher than 88% of companies in the Health Care sector (FY2025). Profit Margin has fluctuated over the past 10 years, ranging from 18.4% in FY2016 to 90.9% in FY2017.
Based on SEC 10-K filings.
31.4% in FY2025 with a 5-year CAGR of -16.1%. Top quartile in the Health Care sector.
Improved from 30.1% to 31.4% over the past 2 years.
Health Care sector context is included.
Profit Margin over time
Growth rates
- 3-Year Change
- -9.9pp
- 5-Year Change
- -16.1pp
- 10-Year Change
- -
Sector benchmark
Top 12% in Health CareTop 12% of 146This company 31.4% Sector average -796.3%
▼
+103.9% above sector average
Key checks
Key Insights
- In FY2025, profit margin increased 1.1% year-over-year.
- Currently 827.7pp above the Health Care sector average.
- Peak profit margin was recorded in FY2017.
- Lowest profit margin in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 3.03 (safe zone, above 2.9 threshold)
- Strong profit margin: 32.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 31.4% | +1.1% |
| FY2024 | 31.1% | +3.1% |
| FY2023 | 30.1% | -27.1% |
| FY2022 | 41.3% | +28.2% |
| FY2021 | 32.3% | -32.1% |
| FY2020 | 47.5% | +47.2% |
| FY2019 | 32.3% | -32.1% |
| FY2018 | 47.5% | -47.7% |
| FY2017 | 90.9% | +393.3% |
| FY2016 | 18.4% | +18.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026